Quick Overview: This presentation provided an overview of the This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... This presentation described the Emerging Technology Program (ETP) and Advanced Manufacturing Technologies Designation ...
Agdd 2024 D2s12 Model Integrated - Detailed Overview & Context
This presentation provided an overview of the This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... This presentation described the Emerging Technology Program (ETP) and Advanced Manufacturing Technologies Designation ... This presentation discussed the ANDA landscape for topical products applied to the skin and identified challenges associated ... This presentation described content and format requirements for composition statements of drug products and explained what to ... This presentation discussed in silico methodologies for topical products applied to the skin, with particular focus on dermal ...
This presentation discussed the complexity of generic oligonucleotides and RLD-equivalence considerations, while reviewing key ... FDA experts demonstrate the FDA's Generic Drug User Fee Amendments (GDUFA) Science and Research Program's ... This presentation examined In Vitro Release Testing (IVRT) for drug products containing nanomaterials, with a specific focus on ... This presentation explored the critical need for improved In Vitro Release Testing (IVRT) methods for complex drug products. dissolution issues and examined OGD's bioequivalence evaluation based on the totality of evidence for this case. The session ... This presentation explained how the totality of evidence was used to support bioequivalence assessment for locally acting ...
This presentation explained factors that could impact first-cycle bioequivalence (BE) adequacy based on observed BE ... This presentation identified recent product-specific guidance (PSG) documents that include detailed language regarding the use ... This presentation explored general constraints in dry powder inhaler (DPI) formulation and manufacturing, while discussing ... This presentation assessed Critical Quality Attributes (CQA) risks for oral solution and suspension products and described first ... The third of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. This presentation described different long-acting injectable (LAI) products and recognized regulatory and scientific challenges for ...
The second of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. This presentation provided an overview of the M13 guideline series and the final M13A guideline, highlighting major changes ...
